Global Opthalmology Drugs Market

Opthalmology Drugs Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Application (Maintenance and Servicing, User Acceptance and Adaptation), Indication (Dry Eye, Glaucoma, Infection/Inflammation/Allergy, Retinal Disorders, Others), Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, Others), Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Others), Therapeutic Class (Anti-Glaucoma, Anti-Infection, Anti-Inflammatory, Anti-Allergy), Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Other Ophthalmic Drug Forms) Players and Region - Global Market Outlook to 2028

Opthalmology Drugs Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 6.31%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Opthalmology Drugs
Opthalmology drug is used to treat eye infections. The increasing number of patients with eye disorders and growing geriatric population driving the demand for Opthalmology drugs. For instance, according to the report published by the Food and Drug Administration in 2018, globally over 1.3 billion people are affected by a different type of vision impairment. The majority of patients with vision impairment are over the age of 50 years. Further, technological advancement in the healthcare industry and increasing healthcare infratstrure in the developing economies expected to drive the demand for ophthalmology drugs over the forecasted period.

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketNorth America
UnitValue (USD Million)
CAGR6.31%


Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Opthalmology Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Medical Optics, Inc. (United States), Carl-Zeiss AG (Germany), Ellex Medical Lasers Ltd. (Australia), Essilor International S.A. (France), Sun Pharma (India), Topcon Corporation (Japan), Novartis AG (Switzerland), Bausch & Lomb, Inc. (United States), ALLERGAN PLC (Ireland), Pfizer, Inc. (United States) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Insight Vision Inc. (United States), Nidek Co.Ltd (Japan), Regeneron Pharmaceuticals, Inc. (United States) and Santen Pharmaceutical (Japan).

Segmentation Overview
AMA Research has segmented the market of Global Opthalmology Drugs market by Type (Prescription Drugs and Over-the-Counter Drugs), Application (Maintenance and Servicing and User Acceptance and Adaptation) and Region.

On the basis of application, Anti-Glaucoma segment is dominating the market in the year 2022

On the basis of geography, the market of Opthalmology Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Spain, Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Indication, the sub-segment i.e. Dry Eye will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Biologics will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic Class, the sub-segment i.e. Anti-Glaucoma will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Form, the sub-segment i.e. Liquid Ophthalmic Drug Forms will boost the Opthalmology Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Development of Combination Therapies for Treating Ophthalmic Disorders and Technological Advancement in the Healthcare Industry

Market Growth Drivers:
Increasing Prevalence of Eye Disorders and Growing Geriatric Population

Challenges:
Lack of Awareness in the Emerging Economies

Restraints:
Stringent Government Regulations Regarding Drugs and Threat of Side Effects Associated With Ophthalmic Drugs

Opportunities:
Increasing Demand of Ophthalmic Drugs for Treatment of Retinal Disorders and Growing Healthcare Infratstrure in the Developing Economies

Market Leaders and their expansionary development strategies
In Dec. 2023 Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) B.V. (D.O.R.C.) from the investment firm Eurazeo SE, Paris, France.
In December 2023,Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) B.V. (D.O.R.C.) from the investment firm Eurazeo SE, Paris, France. The acquisition will enhance and complement ZEISS Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors.
“The Food and Drug Administration (FDA), a regulatory agency within the Department of Health and Human Services, regulates the safety and effectiveness of drugs sold in the United States. FDA divides that responsibility into two phases. In the preapproval (premarket) phase, FDA reviews manufacturers’ applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. Once a drug is on the market, FDA continues its oversight of drug safety and effectiveness. That postapproval (postmarket) phase lasts as long as the drug is on the market.”

Key Target Audience
Opthalmology Drugs Manufacturers, Traders and Distributors of Opthalmology Drugs, Research and Development Institutes, Potential Investors, Nationalized Laboratory, Government and Research Organizations, Trade Associations and Industry Bodies, Commercial Research & Development Institutions and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Prescription Drugs
  • Over-the-Counter Drugs
By Application
  • Maintenance and Servicing
  • User Acceptance and Adaptation
By Indication
  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Others

By Technology
  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small Molecule
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

By Therapeutic Class
  • Anti-Glaucoma
  • Anti-Infection
  • Anti-Inflammatory
  • Anti-Allergy

By Dosage Form
  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Spain
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Eye Disorders
      • 3.2.2. Growing Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Development of Combination Therapies for Treating Ophthalmic Disorders
      • 3.4.2. Technological Advancement in the Healthcare Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Opthalmology Drugs, by Type, Application, Indication, Technology, Distribution Channel, Therapeutic Class, Dosage Form and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Opthalmology Drugs (Value)
      • 5.2.1. Global Opthalmology Drugs by: Type (Value)
        • 5.2.1.1. Prescription Drugs
        • 5.2.1.2. Over-the-Counter Drugs
      • 5.2.2. Global Opthalmology Drugs by: Application (Value)
        • 5.2.2.1. Maintenance and Servicing
        • 5.2.2.2. User Acceptance and Adaptation
      • 5.2.3. Global Opthalmology Drugs by: Indication (Value)
        • 5.2.3.1. Dry Eye
        • 5.2.3.2. Glaucoma
        • 5.2.3.3. Infection/Inflammation/Allergy
        • 5.2.3.4. Retinal Disorders
        • 5.2.3.5. Others
      • 5.2.4. Global Opthalmology Drugs by: Technology (Value)
        • 5.2.4.1. Biologics
        • 5.2.4.2. Cell Therapy
        • 5.2.4.3. Gene Therapy
        • 5.2.4.4. Drug Delivery
        • 5.2.4.5. Small Molecule
        • 5.2.4.6. Others
      • 5.2.5. Global Opthalmology Drugs by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Drug Stores
        • 5.2.5.3. Online Pharmacies
        • 5.2.5.4. Others
      • 5.2.6. Global Opthalmology Drugs by: Therapeutic Class (Value)
        • 5.2.6.1. Anti-Glaucoma
        • 5.2.6.2. Anti-Infection
        • 5.2.6.3. Anti-Inflammatory
        • 5.2.6.4. Anti-Allergy
      • 5.2.7. Global Opthalmology Drugs by: Dosage Form (Value)
        • 5.2.7.1. Liquid Ophthalmic Drug Forms
        • 5.2.7.2. Solid Ophthalmic Drug Forms
        • 5.2.7.3. Semisolid Ophthalmic Drug Forms
        • 5.2.7.4. Multicompartment Drug Delivery Systems
        • 5.2.7.5. Other Ophthalmic Drug Forms
      • 5.2.8. Global Opthalmology Drugs Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Spain
          • 5.2.8.3.2. Germany
          • 5.2.8.3.3. France
          • 5.2.8.3.4. Italy
          • 5.2.8.3.5. United Kingdom
          • 5.2.8.3.6. Netherlands
          • 5.2.8.3.7. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
  • 6. Opthalmology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Medical Optics, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Carl-Zeiss AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ellex Medical Lasers Ltd. (Australia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Essilor International S.A. (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharma (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Topcon Corporation (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bausch & Lomb, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ALLERGAN PLC (Ireland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Opthalmology Drugs Sale, by Type, Application, Indication, Technology, Distribution Channel, Therapeutic Class, Dosage Form and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Opthalmology Drugs (Value)
      • 7.2.1. Global Opthalmology Drugs by: Type (Value)
        • 7.2.1.1. Prescription Drugs
        • 7.2.1.2. Over-the-Counter Drugs
      • 7.2.2. Global Opthalmology Drugs by: Application (Value)
        • 7.2.2.1. Maintenance and Servicing
        • 7.2.2.2. User Acceptance and Adaptation
      • 7.2.3. Global Opthalmology Drugs by: Indication (Value)
        • 7.2.3.1. Dry Eye
        • 7.2.3.2. Glaucoma
        • 7.2.3.3. Infection/Inflammation/Allergy
        • 7.2.3.4. Retinal Disorders
        • 7.2.3.5. Others
      • 7.2.4. Global Opthalmology Drugs by: Technology (Value)
        • 7.2.4.1. Biologics
        • 7.2.4.2. Cell Therapy
        • 7.2.4.3. Gene Therapy
        • 7.2.4.4. Drug Delivery
        • 7.2.4.5. Small Molecule
        • 7.2.4.6. Others
      • 7.2.5. Global Opthalmology Drugs by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Drug Stores
        • 7.2.5.3. Online Pharmacies
        • 7.2.5.4. Others
      • 7.2.6. Global Opthalmology Drugs by: Therapeutic Class (Value)
        • 7.2.6.1. Anti-Glaucoma
        • 7.2.6.2. Anti-Infection
        • 7.2.6.3. Anti-Inflammatory
        • 7.2.6.4. Anti-Allergy
      • 7.2.7. Global Opthalmology Drugs by: Dosage Form (Value)
        • 7.2.7.1. Liquid Ophthalmic Drug Forms
        • 7.2.7.2. Solid Ophthalmic Drug Forms
        • 7.2.7.3. Semisolid Ophthalmic Drug Forms
        • 7.2.7.4. Multicompartment Drug Delivery Systems
        • 7.2.7.5. Other Ophthalmic Drug Forms
      • 7.2.8. Global Opthalmology Drugs Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Spain
          • 7.2.8.3.2. Germany
          • 7.2.8.3.3. France
          • 7.2.8.3.4. Italy
          • 7.2.8.3.5. United Kingdom
          • 7.2.8.3.6. Netherlands
          • 7.2.8.3.7. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Opthalmology Drugs: by Type(USD Million)
  • Table 2. Opthalmology Drugs Prescription Drugs , by Region USD Million (2017-2022)
  • Table 3. Opthalmology Drugs Over-the-Counter Drugs , by Region USD Million (2017-2022)
  • Table 4. Opthalmology Drugs: by Application(USD Million)
  • Table 5. Opthalmology Drugs Maintenance and Servicing , by Region USD Million (2017-2022)
  • Table 6. Opthalmology Drugs User Acceptance and Adaptation , by Region USD Million (2017-2022)
  • Table 7. Opthalmology Drugs: by Indication(USD Million)
  • Table 8. Opthalmology Drugs Dry Eye , by Region USD Million (2017-2022)
  • Table 9. Opthalmology Drugs Glaucoma , by Region USD Million (2017-2022)
  • Table 10. Opthalmology Drugs Infection/Inflammation/Allergy , by Region USD Million (2017-2022)
  • Table 11. Opthalmology Drugs Retinal Disorders , by Region USD Million (2017-2022)
  • Table 12. Opthalmology Drugs Others , by Region USD Million (2017-2022)
  • Table 13. Opthalmology Drugs: by Technology(USD Million)
  • Table 14. Opthalmology Drugs Biologics , by Region USD Million (2017-2022)
  • Table 15. Opthalmology Drugs Cell Therapy , by Region USD Million (2017-2022)
  • Table 16. Opthalmology Drugs Gene Therapy , by Region USD Million (2017-2022)
  • Table 17. Opthalmology Drugs Drug Delivery , by Region USD Million (2017-2022)
  • Table 18. Opthalmology Drugs Small Molecule , by Region USD Million (2017-2022)
  • Table 19. Opthalmology Drugs Others , by Region USD Million (2017-2022)
  • Table 20. Opthalmology Drugs: by Distribution Channel(USD Million)
  • Table 21. Opthalmology Drugs Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 22. Opthalmology Drugs Drug Stores , by Region USD Million (2017-2022)
  • Table 23. Opthalmology Drugs Online Pharmacies , by Region USD Million (2017-2022)
  • Table 24. Opthalmology Drugs Others , by Region USD Million (2017-2022)
  • Table 25. Opthalmology Drugs: by Therapeutic Class(USD Million)
  • Table 26. Opthalmology Drugs Anti-Glaucoma , by Region USD Million (2017-2022)
  • Table 27. Opthalmology Drugs Anti-Infection , by Region USD Million (2017-2022)
  • Table 28. Opthalmology Drugs Anti-Inflammatory , by Region USD Million (2017-2022)
  • Table 29. Opthalmology Drugs Anti-Allergy , by Region USD Million (2017-2022)
  • Table 30. Opthalmology Drugs: by Dosage Form(USD Million)
  • Table 31. Opthalmology Drugs Liquid Ophthalmic Drug Forms , by Region USD Million (2017-2022)
  • Table 32. Opthalmology Drugs Solid Ophthalmic Drug Forms , by Region USD Million (2017-2022)
  • Table 33. Opthalmology Drugs Semisolid Ophthalmic Drug Forms , by Region USD Million (2017-2022)
  • Table 34. Opthalmology Drugs Multicompartment Drug Delivery Systems , by Region USD Million (2017-2022)
  • Table 35. Opthalmology Drugs Other Ophthalmic Drug Forms , by Region USD Million (2017-2022)
  • Table 36. South America Opthalmology Drugs, by Country USD Million (2017-2022)
  • Table 37. South America Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 38. South America Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 39. South America Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 40. South America Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 41. South America Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 42. South America Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 43. South America Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 44. Brazil Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 45. Brazil Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 46. Brazil Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 47. Brazil Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 48. Brazil Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 49. Brazil Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 50. Brazil Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 51. Argentina Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 52. Argentina Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 53. Argentina Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 54. Argentina Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 55. Argentina Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 56. Argentina Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 57. Argentina Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 58. Rest of South America Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 59. Rest of South America Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 60. Rest of South America Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 61. Rest of South America Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 62. Rest of South America Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 63. Rest of South America Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 64. Rest of South America Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 65. Asia Pacific Opthalmology Drugs, by Country USD Million (2017-2022)
  • Table 66. Asia Pacific Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 67. Asia Pacific Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 68. Asia Pacific Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 69. Asia Pacific Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 70. Asia Pacific Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 71. Asia Pacific Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 72. Asia Pacific Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 73. China Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 74. China Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 75. China Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 76. China Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 77. China Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 78. China Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 79. China Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 80. Japan Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 81. Japan Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 82. Japan Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 83. Japan Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 84. Japan Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 85. Japan Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 86. Japan Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 87. India Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 88. India Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 89. India Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 90. India Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 91. India Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 92. India Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 93. India Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 94. South Korea Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 95. South Korea Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 96. South Korea Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 97. South Korea Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 98. South Korea Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 99. South Korea Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 100. South Korea Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 101. Taiwan Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 102. Taiwan Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 103. Taiwan Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 104. Taiwan Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 105. Taiwan Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 106. Taiwan Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 107. Taiwan Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 108. Australia Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 109. Australia Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 110. Australia Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 111. Australia Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 112. Australia Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 113. Australia Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 114. Australia Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 115. Rest of Asia-Pacific Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 116. Rest of Asia-Pacific Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 117. Rest of Asia-Pacific Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 118. Rest of Asia-Pacific Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 119. Rest of Asia-Pacific Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 120. Rest of Asia-Pacific Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 121. Rest of Asia-Pacific Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 122. Europe Opthalmology Drugs, by Country USD Million (2017-2022)
  • Table 123. Europe Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 124. Europe Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 125. Europe Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 126. Europe Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 127. Europe Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 128. Europe Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 129. Europe Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 130. Spain Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 131. Spain Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 132. Spain Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 133. Spain Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 134. Spain Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 135. Spain Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 136. Spain Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 137. Germany Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 138. Germany Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 139. Germany Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 140. Germany Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 141. Germany Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 142. Germany Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 143. Germany Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 144. France Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 145. France Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 146. France Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 147. France Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 148. France Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 149. France Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 150. France Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 151. Italy Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 152. Italy Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 153. Italy Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 154. Italy Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 155. Italy Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 156. Italy Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 157. Italy Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 158. United Kingdom Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 159. United Kingdom Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 160. United Kingdom Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 161. United Kingdom Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 162. United Kingdom Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 163. United Kingdom Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 164. United Kingdom Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 165. Netherlands Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 166. Netherlands Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 167. Netherlands Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 168. Netherlands Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 169. Netherlands Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 170. Netherlands Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 171. Netherlands Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 172. Rest of Europe Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 173. Rest of Europe Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 174. Rest of Europe Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 175. Rest of Europe Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 176. Rest of Europe Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 177. Rest of Europe Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 178. Rest of Europe Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 179. MEA Opthalmology Drugs, by Country USD Million (2017-2022)
  • Table 180. MEA Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 181. MEA Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 182. MEA Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 183. MEA Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 184. MEA Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 185. MEA Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 186. MEA Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 187. Middle East Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 188. Middle East Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 189. Middle East Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 190. Middle East Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 191. Middle East Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 192. Middle East Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 193. Middle East Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 194. Africa Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 195. Africa Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 196. Africa Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 197. Africa Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 198. Africa Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 199. Africa Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 200. Africa Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 201. North America Opthalmology Drugs, by Country USD Million (2017-2022)
  • Table 202. North America Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 203. North America Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 204. North America Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 205. North America Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 206. North America Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 207. North America Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 208. North America Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 209. United States Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 210. United States Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 211. United States Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 212. United States Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 213. United States Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 214. United States Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 215. United States Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 216. Canada Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 217. Canada Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 218. Canada Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 219. Canada Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 220. Canada Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 221. Canada Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 222. Canada Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 223. Mexico Opthalmology Drugs, by Type USD Million (2017-2022)
  • Table 224. Mexico Opthalmology Drugs, by Application USD Million (2017-2022)
  • Table 225. Mexico Opthalmology Drugs, by Indication USD Million (2017-2022)
  • Table 226. Mexico Opthalmology Drugs, by Technology USD Million (2017-2022)
  • Table 227. Mexico Opthalmology Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 228. Mexico Opthalmology Drugs, by Therapeutic Class USD Million (2017-2022)
  • Table 229. Mexico Opthalmology Drugs, by Dosage Form USD Million (2017-2022)
  • Table 230. Company Basic Information, Sales Area and Its Competitors
  • Table 231. Company Basic Information, Sales Area and Its Competitors
  • Table 232. Company Basic Information, Sales Area and Its Competitors
  • Table 233. Company Basic Information, Sales Area and Its Competitors
  • Table 234. Company Basic Information, Sales Area and Its Competitors
  • Table 235. Company Basic Information, Sales Area and Its Competitors
  • Table 236. Company Basic Information, Sales Area and Its Competitors
  • Table 237. Company Basic Information, Sales Area and Its Competitors
  • Table 238. Company Basic Information, Sales Area and Its Competitors
  • Table 239. Company Basic Information, Sales Area and Its Competitors
  • Table 240. Company Basic Information, Sales Area and Its Competitors
  • Table 241. Opthalmology Drugs: by Type(USD Million)
  • Table 242. Opthalmology Drugs Prescription Drugs , by Region USD Million (2023-2028)
  • Table 243. Opthalmology Drugs Over-the-Counter Drugs , by Region USD Million (2023-2028)
  • Table 244. Opthalmology Drugs: by Application(USD Million)
  • Table 245. Opthalmology Drugs Maintenance and Servicing , by Region USD Million (2023-2028)
  • Table 246. Opthalmology Drugs User Acceptance and Adaptation , by Region USD Million (2023-2028)
  • Table 247. Opthalmology Drugs: by Indication(USD Million)
  • Table 248. Opthalmology Drugs Dry Eye , by Region USD Million (2023-2028)
  • Table 249. Opthalmology Drugs Glaucoma , by Region USD Million (2023-2028)
  • Table 250. Opthalmology Drugs Infection/Inflammation/Allergy , by Region USD Million (2023-2028)
  • Table 251. Opthalmology Drugs Retinal Disorders , by Region USD Million (2023-2028)
  • Table 252. Opthalmology Drugs Others , by Region USD Million (2023-2028)
  • Table 253. Opthalmology Drugs: by Technology(USD Million)
  • Table 254. Opthalmology Drugs Biologics , by Region USD Million (2023-2028)
  • Table 255. Opthalmology Drugs Cell Therapy , by Region USD Million (2023-2028)
  • Table 256. Opthalmology Drugs Gene Therapy , by Region USD Million (2023-2028)
  • Table 257. Opthalmology Drugs Drug Delivery , by Region USD Million (2023-2028)
  • Table 258. Opthalmology Drugs Small Molecule , by Region USD Million (2023-2028)
  • Table 259. Opthalmology Drugs Others , by Region USD Million (2023-2028)
  • Table 260. Opthalmology Drugs: by Distribution Channel(USD Million)
  • Table 261. Opthalmology Drugs Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 262. Opthalmology Drugs Drug Stores , by Region USD Million (2023-2028)
  • Table 263. Opthalmology Drugs Online Pharmacies , by Region USD Million (2023-2028)
  • Table 264. Opthalmology Drugs Others , by Region USD Million (2023-2028)
  • Table 265. Opthalmology Drugs: by Therapeutic Class(USD Million)
  • Table 266. Opthalmology Drugs Anti-Glaucoma , by Region USD Million (2023-2028)
  • Table 267. Opthalmology Drugs Anti-Infection , by Region USD Million (2023-2028)
  • Table 268. Opthalmology Drugs Anti-Inflammatory , by Region USD Million (2023-2028)
  • Table 269. Opthalmology Drugs Anti-Allergy , by Region USD Million (2023-2028)
  • Table 270. Opthalmology Drugs: by Dosage Form(USD Million)
  • Table 271. Opthalmology Drugs Liquid Ophthalmic Drug Forms , by Region USD Million (2023-2028)
  • Table 272. Opthalmology Drugs Solid Ophthalmic Drug Forms , by Region USD Million (2023-2028)
  • Table 273. Opthalmology Drugs Semisolid Ophthalmic Drug Forms , by Region USD Million (2023-2028)
  • Table 274. Opthalmology Drugs Multicompartment Drug Delivery Systems , by Region USD Million (2023-2028)
  • Table 275. Opthalmology Drugs Other Ophthalmic Drug Forms , by Region USD Million (2023-2028)
  • Table 276. South America Opthalmology Drugs, by Country USD Million (2023-2028)
  • Table 277. South America Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 278. South America Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 279. South America Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 280. South America Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 281. South America Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 282. South America Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 283. South America Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 284. Brazil Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 285. Brazil Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 286. Brazil Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 287. Brazil Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 288. Brazil Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 289. Brazil Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 290. Brazil Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 291. Argentina Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 292. Argentina Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 293. Argentina Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 294. Argentina Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 295. Argentina Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 296. Argentina Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 297. Argentina Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 298. Rest of South America Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 299. Rest of South America Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 300. Rest of South America Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 301. Rest of South America Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 302. Rest of South America Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 303. Rest of South America Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 304. Rest of South America Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 305. Asia Pacific Opthalmology Drugs, by Country USD Million (2023-2028)
  • Table 306. Asia Pacific Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 307. Asia Pacific Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 308. Asia Pacific Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 309. Asia Pacific Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 310. Asia Pacific Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 311. Asia Pacific Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 312. Asia Pacific Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 313. China Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 314. China Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 315. China Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 316. China Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 317. China Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 318. China Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 319. China Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 320. Japan Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 321. Japan Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 322. Japan Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 323. Japan Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 324. Japan Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 325. Japan Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 326. Japan Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 327. India Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 328. India Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 329. India Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 330. India Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 331. India Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 332. India Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 333. India Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 334. South Korea Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 335. South Korea Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 336. South Korea Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 337. South Korea Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 338. South Korea Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 339. South Korea Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 340. South Korea Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 341. Taiwan Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 342. Taiwan Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 343. Taiwan Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 344. Taiwan Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 345. Taiwan Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 346. Taiwan Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 347. Taiwan Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 348. Australia Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 349. Australia Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 350. Australia Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 351. Australia Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 352. Australia Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 353. Australia Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 354. Australia Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 355. Rest of Asia-Pacific Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 356. Rest of Asia-Pacific Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 357. Rest of Asia-Pacific Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 358. Rest of Asia-Pacific Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 359. Rest of Asia-Pacific Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 360. Rest of Asia-Pacific Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 361. Rest of Asia-Pacific Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 362. Europe Opthalmology Drugs, by Country USD Million (2023-2028)
  • Table 363. Europe Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 364. Europe Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 365. Europe Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 366. Europe Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 367. Europe Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 368. Europe Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 369. Europe Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 370. Spain Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 371. Spain Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 372. Spain Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 373. Spain Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 374. Spain Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 375. Spain Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 376. Spain Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 377. Germany Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 378. Germany Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 379. Germany Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 380. Germany Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 381. Germany Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 382. Germany Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 383. Germany Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 384. France Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 385. France Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 386. France Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 387. France Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 388. France Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 389. France Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 390. France Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 391. Italy Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 392. Italy Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 393. Italy Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 394. Italy Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 395. Italy Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 396. Italy Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 397. Italy Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 398. United Kingdom Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 399. United Kingdom Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 400. United Kingdom Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 401. United Kingdom Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 402. United Kingdom Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 403. United Kingdom Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 404. United Kingdom Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 405. Netherlands Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 406. Netherlands Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 407. Netherlands Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 408. Netherlands Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 409. Netherlands Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 410. Netherlands Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 411. Netherlands Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 412. Rest of Europe Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 413. Rest of Europe Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 414. Rest of Europe Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 415. Rest of Europe Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 416. Rest of Europe Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 417. Rest of Europe Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 418. Rest of Europe Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 419. MEA Opthalmology Drugs, by Country USD Million (2023-2028)
  • Table 420. MEA Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 421. MEA Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 422. MEA Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 423. MEA Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 424. MEA Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 425. MEA Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 426. MEA Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 427. Middle East Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 428. Middle East Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 429. Middle East Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 430. Middle East Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 431. Middle East Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 432. Middle East Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 433. Middle East Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 434. Africa Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 435. Africa Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 436. Africa Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 437. Africa Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 438. Africa Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 439. Africa Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 440. Africa Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 441. North America Opthalmology Drugs, by Country USD Million (2023-2028)
  • Table 442. North America Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 443. North America Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 444. North America Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 445. North America Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 446. North America Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 447. North America Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 448. North America Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 449. United States Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 450. United States Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 451. United States Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 452. United States Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 453. United States Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 454. United States Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 455. United States Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 456. Canada Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 457. Canada Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 458. Canada Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 459. Canada Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 460. Canada Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 461. Canada Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 462. Canada Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 463. Mexico Opthalmology Drugs, by Type USD Million (2023-2028)
  • Table 464. Mexico Opthalmology Drugs, by Application USD Million (2023-2028)
  • Table 465. Mexico Opthalmology Drugs, by Indication USD Million (2023-2028)
  • Table 466. Mexico Opthalmology Drugs, by Technology USD Million (2023-2028)
  • Table 467. Mexico Opthalmology Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 468. Mexico Opthalmology Drugs, by Therapeutic Class USD Million (2023-2028)
  • Table 469. Mexico Opthalmology Drugs, by Dosage Form USD Million (2023-2028)
  • Table 470. Research Programs/Design for This Report
  • Table 471. Key Data Information from Secondary Sources
  • Table 472. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Opthalmology Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Opthalmology Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Opthalmology Drugs: by Indication USD Million (2017-2022)
  • Figure 7. Global Opthalmology Drugs: by Technology USD Million (2017-2022)
  • Figure 8. Global Opthalmology Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 9. Global Opthalmology Drugs: by Therapeutic Class USD Million (2017-2022)
  • Figure 10. Global Opthalmology Drugs: by Dosage Form USD Million (2017-2022)
  • Figure 11. South America Opthalmology Drugs Share (%), by Country
  • Figure 12. Asia Pacific Opthalmology Drugs Share (%), by Country
  • Figure 13. Europe Opthalmology Drugs Share (%), by Country
  • Figure 14. MEA Opthalmology Drugs Share (%), by Country
  • Figure 15. North America Opthalmology Drugs Share (%), by Country
  • Figure 16. Global Opthalmology Drugs share by Players 2022 (%)
  • Figure 17. Global Opthalmology Drugs share by Players (Top 3) 2022(%)
  • Figure 18. Global Opthalmology Drugs share by Players (Top 5) 2022(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Abbott Medical Optics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott Medical Optics, Inc. (United States) Revenue: by Geography 2022
  • Figure 22. Carl-Zeiss AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Carl-Zeiss AG (Germany) Revenue: by Geography 2022
  • Figure 24. Ellex Medical Lasers Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 25. Ellex Medical Lasers Ltd. (Australia) Revenue: by Geography 2022
  • Figure 26. Essilor International S.A. (France) Revenue, Net Income and Gross profit
  • Figure 27. Essilor International S.A. (France) Revenue: by Geography 2022
  • Figure 28. Sun Pharma (India) Revenue, Net Income and Gross profit
  • Figure 29. Sun Pharma (India) Revenue: by Geography 2022
  • Figure 30. Topcon Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Topcon Corporation (Japan) Revenue: by Geography 2022
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 34. Bausch & Lomb, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bausch & Lomb, Inc. (United States) Revenue: by Geography 2022
  • Figure 36. ALLERGAN PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 37. ALLERGAN PLC (Ireland) Revenue: by Geography 2022
  • Figure 38. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Pfizer, Inc. (United States) Revenue: by Geography 2022
  • Figure 40. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 41. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 42. Global Opthalmology Drugs: by Type USD Million (2023-2028)
  • Figure 43. Global Opthalmology Drugs: by Application USD Million (2023-2028)
  • Figure 44. Global Opthalmology Drugs: by Indication USD Million (2023-2028)
  • Figure 45. Global Opthalmology Drugs: by Technology USD Million (2023-2028)
  • Figure 46. Global Opthalmology Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 47. Global Opthalmology Drugs: by Therapeutic Class USD Million (2023-2028)
  • Figure 48. Global Opthalmology Drugs: by Dosage Form USD Million (2023-2028)
  • Figure 49. South America Opthalmology Drugs Share (%), by Country
  • Figure 50. Asia Pacific Opthalmology Drugs Share (%), by Country
  • Figure 51. Europe Opthalmology Drugs Share (%), by Country
  • Figure 52. MEA Opthalmology Drugs Share (%), by Country
  • Figure 53. North America Opthalmology Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Medical Optics, Inc. (United States)
  • Carl-Zeiss AG (Germany)
  • Ellex Medical Lasers Ltd. (Australia)
  • Essilor International S.A. (France)
  • Sun Pharma (India)
  • Topcon Corporation (Japan)
  • Novartis AG (Switzerland)
  • Bausch & Lomb, Inc. (United States)
  • ALLERGAN PLC (Ireland)
  • Pfizer, Inc. (United States)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Insight Vision Inc. (United States) , Nidek Co.Ltd (Japan) , Regeneron Pharmaceuticals, Inc. (United States) , Santen Pharmaceutical (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 136 Pages 60 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Opthalmology Drugs Market Quantitative research analysis
Global Opthalmology Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Medical Optics, Inc. (United States), Carl-Zeiss AG (Germany), Ellex Medical Lasers Ltd. (Australia), Essilor International S.A. (France), Sun Pharma (India), Topcon Corporation (Japan), Novartis AG (Switzerland), Bausch & Lomb, Inc. (United States), ALLERGAN PLC (Ireland), Pfizer, Inc. (United States) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Development of Combination Therapies for Treating Ophthalmic Disorders " is seen as one of major influencing trends for Opthalmology Drugs Market during projected period 2022-2028.
The Opthalmology Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Opthalmology Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Antihistamine Drugs Comprehensive Study by Type (Sedating (Brompheniramine, Chlorpheniramine, Diphenhydramine, Doxylamine, Carbinoxamine, and Others), Non-Sedating Antihistamines (Fexofenadine, Lorat...
$ 3750
Embolotherapy Comprehensive Study by Type (Embolic Agents, Microspheres, Embolic Coils (Detachable Coils, Pushable Coils), Liquid Embolic Agents, Embolic Plug Systems, Detachable Balloons, Support De...
$ 4800
Plaque Psoriasis Treatment Comprehensive Study by Type (Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies), Application (Hospitals, Clinics, Others), Drug Class (TNF-α Inhibitor...
$ 3350
Cerebral Infarction Therapy Comprehensive Study by Type (Partial Anterior Circulation Infarct (PACI), Total Anterior Circulation Infarct (TACI), Posterior Circulation Infarct (POCI)), Application (Ho...
$ 3650
Smokeless Tobacco Treatment  Comprehensive Study by Type (Keratosis Treatment, Addiction Treatment, Disease Treatment), Application (Hospitals & Clinics, Academic & Research Organizations, Pharmacies...
$ 3750
Anaplastic Thyroid Cancer Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgery Centers), Treatment (Surgery, Radiation Therapy, Chemotherapy, Other), Diagnosis (Imaging (Ultraso...
$ 3350